August 2012 — The global resurgence of tuberculosis (TB) over the past decades has been fueled by emerging drug resistance, co-infection with increasingly prevalent HIV and decreasing investments in public health systems. These challenges call for innovative, strategic approaches and more efficient, cost-effective programs. TB CARE I is a coalition of seven international TB control organizations, each with offices in most of the U.S. Agency for International Development’s TB-priority countries. The locations of these offices ensure cost-effectiveness and efficiency. FHI 360 is the lead coordinating partner in Cambodia, Mozambique and Zambia and a collaborating partner in Indonesia and Nigeria. The program focuses on specific technical areas, including early case detection, improved laboratory capacity, management of drug-resistant TB, TB/HIV co-infection and health systems strengthening.
FHI 360 and TB CARE I assist countries to move toward universal access to TB treatment by reaching out to communities most at risk and working to reduce morbidity and mortality through increased case detection and treatment.
TB CARE I: Year 1 Summary
January 2011 — The global resurgence of tuberculosis (TB) over the past decades has been fueled by emerging drug resistance, co-infection with increasingly prevalent HIV and decreasing investments in public health systems. These challenges call for innovative, strategic approaches and more efficient, cost-effective programs. TB CARE I is a coalition of seven international TB control organizations, each with offices in most of the U.S. Agency for International Development’s TB-priority countries. The locations of these offices ensure cost-effectiveness and efficiency. FHI 360 is the lead coordinating partner in Cambodia, Mozambique and Zambia and a collaborating partner in Indonesia and Nigeria. The program focuses on specific technical areas, including early case detection, improved laboratory capacity, management of drug-resistant TB, HIV/TB co-infection and health systems strengthening.
FHI 360 and TB CARE I assist countries to move toward universal access to TB treatment by reaching out to communities most at risk and working to reduce morbidity and mortality through increased case detection and treatment.
TB CAP Summary Report
2010 — The global resurgence of tuberculosis (TB) over the past decades has been fueled by emerging drug resistance, co-infection with increasingly prevalent HIV and decreasing investments in public health systems. These challenges call for innovative, strategic approaches and more efficient, cost-effective programs. TB CARE I is a coalition of seven international TB control organizations, each with offices in most of the U.S. Agency for International Development’s TB- priority countries. The locations of these offices ensure cost-effectiveness and efficiency. FHI 360 is the lead coordinating partner in Cambodia, Mozambique and Zambia and a collaborating partner in Indonesia and Nigeria. The program focuses on specific technical areas, including early case detection, improved laboratory capacity, management of drug-resistant TB, TB/HIV co-infection and health systems strengthening.
FHI 360 and TB CARE I assist countries to move toward universal access to TB treatment by reaching out to communities most at risk and working to reduce morbidity and mortality through increased case detection and treatment.
TB CAP Final Report: 2005-2010
2010 — The global resurgence of tuberculosis (TB) over the past decades has been fueled by emerging drug resistance, co-infection with increasingly prevalent HIV and decreasing investments in public health systems. These challenges call for innovative, strategic approaches and more efficient, cost-effective programs. TB CARE I is a coalition of seven international TB control organizations, each with offices in most of the U.S. Agency for International Development’s TB-priority countries. The locations of these offices ensure cost-effectiveness and efficiency. FHI 360 is the lead coordinating partner in Cambodia, Mozambique and Zambia and a collaborating partner in Indonesia and Nigeria. The program focuses on specific technical areas, including early case detection, improved laboratory capacity, management of drug-resistant TB, TB/HIV co-infection and health systems strengthening.
FHI 360 and TB CARE I assist countries to move toward universal access to TB treatment by reaching out to communities most at risk and working to reduce morbidity and mortality through increased case detection and treatment.
